Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics’ Skyline Medical Division Expands Presence in Australia with Three New STREAMWAY Systems at Wangaratta Hospital in Victoria
MINNEAPOLIS , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces its Skyline Medical division, producer of the FDA-approved and CE-marked  STREAMWAY ® System  for automated, direct-to-drain medical fluid disposal, has received
View HTML
Toggle Summary Precision Therapeutics’ TumorGenesis Division Isolates Discovery Biomarkers for Thyroid Cancer Cell Types, Initiating Its Proprietary Process for New Drug Development Via Patient-Derived Tumor Models
MINNEAPOLIS , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces its TumorGenesis subsidiary has identified three thyroid cancer cell types and has isolated the discovery biomarkers.  The company will utilize this discovery to
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Widens Global Reach Through New Taiwanese Distribution Agreement with Winner Scientific
Company Further Expands Global Outreach Through Exhibition at Arab Health Show in Dubai MINNEAPOLIS , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, producer of the FDA-approved and
View HTML
Toggle Summary Precision Therapeutics Receives $1,370,000 Investment from CEO and Director, Carl Schwartz
MINNEAPOLIS , Jan. 18, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its chief executive officer and director, Carl Schwartz , has made an additional investment of $1,000,000 in the Company, effective January 8, 2019 .
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Significantly Expands Footprint in New England With Sale of Six STREAMWAY Systems to Yale University Ambulatory Outpatient Surgical Center
Large Sale to Prestigious Health System Further Validates STREAMLINE Utility MINNEAPOLIS , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked 
View HTML
Toggle Summary Precision Therapeutics Reports Third Quarter 2018 Financial Results
MINNEAPOLIS , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today financial results for the three and nine months ended
View HTML
Toggle Summary Precision Therapeutics to Hold Business Update Conference Call on November 14, 2018
MINNEAPOLIS , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its financial results for the
View HTML
Toggle Summary Precision Therapeutics Secures Rights to Novel Technology Designed To Develop Drugs That Target Specific Cancer by Its Mutation
MINNEAPOLIS , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has acquired rights to technology for the proprietary
View HTML
Toggle Summary Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Precision Therapeutics Inc.: SEC File Nos. 001-36790; and 333-221966
Precision Therapeutics Files Form S-4 Regarding Proposed Merger with Helomics Holding Corporation MINNEAPOLIS , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine
View HTML
Toggle Summary Precision Therapeutics Continues to Build World Class Scientific Advisory Board with Appointment of Hector J. Gomez, MD, PhD
MINNEAPOLIS , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has appointed Dr. Hector J. Gomez , President & CEO, Co-Founder of GLG
View HTML